Published Study Finds 9/10 Chronic Wound Patients Likely to Have Received More Appropriately Triaged Care with Information from the MolecuLight i:X® Imaging Device

September 13, 2019 -Study Highlights the Utility of Bacterial Fluorescence Imaging to Provide Real-Time Information to Clinicians on a Wound’s Bacterial Burden that Significantly Impacted Treatment Decisions Read More

Oxford Finance LLC Provides $7.5M USD Term Loan to MolecuLight®Inc. to Support Global Commercial Expansion

August 19, 2019 -

TORONTO, Canada – (August 19, 2019) MolecuLight Inc., the world’s leader in handheld fluorescence imaging for real-time visualization of bacteria for chronic wounds, announced it has secured a $7.5 million USD term loan from Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services

photonamic GmbH & Co. KG (Germany) Acquires the Oncology Business from MolecuLight® Inc. (Canada)

August 14, 2019 -

photonamic GmbH & Co. KG (Head office: Pinneberg, Germany; CEO: Ulrich Kosciessa, Ph.D.) (“photonamic”), a subsidiary of SBI Holdings, Inc. (Head office: Minato-ku,Tokyo; Representative Director, President and CEO: Yoshitaka Kitao) is engaged in the business of pharmaceutical development of 5-aminolevulinic acid (“5-ALA”) (*) hereby announces the acquisition of the

MolecuLight® Inc.’s first-of-its-kind handheld fluorescence imaging device receives FDA De Novo clearance for US wound care market

August 14, 2018 -MolecuLight Inc. achieved a major regulatory milestone permitting expansion into the United States market. FDA has granted De Novo clearance for the ground-breaking wound fluorescence imaging device, the MolecuLight i:X.  Read More

MolecuLight announces appointment of Anil Amlani as CEO

October 17, 2017 -

TORONTO, CANADA.  MolecuLight, a global leader in fluorescence image-guidance solutions, is pleased to announce the appointment of industry veteran Anil Amlani as Chief Executive Officer effective September 29, 2017.

William Wignall, Chairman of the Board at MolecuLight, commented, “The Board is delighted to welcome Anil as MolecuLight’s new CEO. Anil

MolecuLight Inc. ranked in the top 6 at the 2016 Medical Design Excellence Awards

June 21, 2016 -This premier awards program for the medtech industry announced the 2016 winners

Toronto, June 21, 2016: The Medical Design Excellence Awards (MDEA), the premier awards program for the medtech industry announced the 2016 winners on Tuesday, June 14th at a special ceremony at the MD&M East conference and exposition in

MolecuLight announces Health Canada approval for the MolecuLight i:X, its first diagnostic medical imaging device for wound care

October 20, 2015 -MolecuLight Inc. has been authorized to sell the MolecuLight i:X by Health Canada

TORONTO, Oct. 20, 2015 /CNW/ – MolecuLight ® Inc. has been authorized to sell the MolecuLight i:X by Health Canada. The approval will allow the company to begin selling the product throughout Canada.  MolecuLight i:X is a novel, handheld fluorescence

MolecuLight receives $990,000 from FedDev Ontario to complete commercialization of a new clinical wound imaging technology

November 28, 2014 -This important financial support will allow MolecuLight to accelerate commercialization

This important financial support will allow MolecuLight to accelerate commercialization of its unique patented handheld fluorescence-imaging platform, which will enable clinicians to detect bacteria in chronic wounds, in real-time and at the point-of-care. MolecuLight’s technology addresses an important problem in